Secukinumab and ixekizumab are anti-IL-17A biologics approved for psoriasis. Compared to anti-TNF biologics (adalimumab), they are CONTRAINDICATED in patients with:
- A Psoriatic arthritis
- B Active inflammatory bowel disease (Crohn's disease) ✓
- C Ankylosing spondylitis
- D Moderate-to-severe plaque psoriasis
Correct answer: B. Active inflammatory bowel disease (Crohn's disease)
Explanation
Anti-IL-17A agents (secukinumab, ixekizumab, bimekizumab) are effective for psoriasis and psoriatic arthritis but are contraindicated or require caution in patients with active inflammatory bowel disease—particularly Crohn's disease—as IL-17 plays a protective role in gut mucosal immunity, and its blockade can exacerbate or unmask IBD. In contrast, anti-TNF biologics like adalimumab have established efficacy in both psoriasis and IBD. Anti-IL-17 agents are approved and effective for ankylosing spondylitis and PsA.
Reference: Neena Khanna Illustrated Synopsis of Dermatology & STD, 6th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.